Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...
DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...
C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...
Stockholm, Sweden Saturday, February 22, 2025, 09:00 Hrs [IST] ...
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
The European Medicines Agency (EMA) has unveiled a pilot scheme for 'adaptive licensing' in which innovative new drugs will be released to patients before they have been given final regulatory ...
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
With authorization from the European Medicines Agency (EMA) to manufacture cell therapies for the European market, C3i positions itself on the global biotechnology stage as Canada's pre-eminent ...
The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results